Major Biological Effects of Neurotrophic Factors on Retinal Ganglion Cells in Mammals

Neurosignals ◽  
1998 ◽  
Vol 7 (4) ◽  
pp. 220-226 ◽  
Author(s):  
Qi Cui ◽  
Kwok-Fai So ◽  
Henry K. Yip
Keyword(s):  
Retinal Ganglion Cells ◽  
Neurotrophic Factors ◽  
Ganglion Cells ◽  
Biological Effects ◽  
Retinal Ganglion

Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury: A quantitative in vivo study

2009 ◽  
Vol 89 (1) ◽  
pp. 32-41 ◽  
Author(s):  
Guillermo Parrilla-Reverter ◽  
Marta Agudo ◽  
Paloma Sobrado-Calvo ◽  
Manuel Salinas-Navarro ◽  
María P. Villegas-Pérez ◽  
...  
Keyword(s):  
Retinal Ganglion Cells ◽  
Neurotrophic Factors ◽  
Ganglion Cells ◽  
Crush Injury ◽  
In Vivo Study ◽  
Retinal Ganglion ◽  
Nerve Crush ◽  
Nerve Crush Injury

scholarly journals Target-Derived Neurotrophic Factor Deprivation Puts Retinal Ganglion Cells on Death Row: Cold Hard Evidence and Caveats

2019 ◽  
Vol 20 (17) ◽  
pp. 4314 ◽  
Author(s):  
Marie Claes ◽  
Lies De Groef ◽  
Lieve Moons
Keyword(s):  
Animal Models ◽  
Disease Progression ◽  
Retinal Ganglion Cells ◽  
Neurotrophic Factors ◽  
Neurotrophic Factor ◽  
Ganglion Cells ◽  
Retrograde Transport ◽  
Retinal Ganglion ◽  
Hard Evidence ◽  
Glaucoma Treatment

Glaucoma and other optic neuropathies are characterized by axonal transport deficits. Axonal cargo travels back and forth between the soma and the axon terminus, a mechanism ensuring homeostasis and the viability of a neuron. An example of vital molecules in the axonal cargo are neurotrophic factors (NTFs). Hindered retrograde transport can cause a scarcity of those factors in the retina, which in turn can tilt the fate of retinal ganglion cells (RGCs) towards apoptosis. This postulation is one of the most widely recognized theories to explain RGC death in the disease progression of glaucoma and is known as the NTF deprivation theory. For several decades, research has been focused on the use of NTFs as a novel neuroprotective glaucoma treatment. Until now, results in animal models have been promising, but translation to the clinic has been highly disappointing. Are we lacking important knowledge to lever NTF therapies towards the therapeutic armamentarium? Or did we get the wrong end of the stick regarding the NTF deprivation theory? In this review, we will tackle the existing evidence and caveats advocating for and against the target-derived NTF deprivation theory in glaucoma, whilst digging into associated therapy efforts.

scholarly journals Human Wharton’s jelly mesenchymal stem cells protect axotomized rat retinal ganglion cells via secretion of anti-inflammatory and neurotrophic factors

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Jose E. Millán-Rivero ◽  
Francisco M. Nadal-Nicolás ◽  
David García-Bernal ◽  
Paloma Sobrado-Calvo ◽  
Miguel Blanquer ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Retinal Ganglion Cells ◽  
Neurotrophic Factors ◽  
Ganglion Cells ◽  
Wharton’S Jelly ◽  
Retinal Ganglion ◽  
Wharton's Jelly ◽  
Anti Inflammatory

scholarly journals Cell-Based Neuroprotection of Retinal Ganglion Cells in Animal Models of Optic Neuropathies

Biology ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1181
Author(s):  
Yue Hu ◽  
Lynn Michelle Grodzki ◽  
Susanne Bartsch ◽  
Udo Bartsch
Keyword(s):  
Animal Models ◽  
Ganglion Cell ◽  
Retinal Ganglion Cells ◽  
Neurotrophic Factors ◽  
Visual Information ◽  
Therapeutic Potential ◽  
Ganglion Cells ◽  
Treatment Strategies ◽  
Projection Neurons ◽  
Retinal Ganglion

Retinal ganglion cells (RGCs) comprise a heterogenous group of projection neurons that transmit visual information from the retina to the brain. Progressive degeneration of these cells, as it occurs in inflammatory, ischemic, traumatic or glaucomatous optic neuropathies, results in visual deterioration and is among the leading causes of irreversible blindness. Treatment options for these diseases are limited. Neuroprotective approaches aim to slow down and eventually halt the loss of ganglion cells in these disorders. In this review, we have summarized preclinical studies that have evaluated the efficacy of cell-based neuroprotective treatment strategies to rescue retinal ganglion cells from cell death. Intraocular transplantations of diverse genetically nonmodified cell types or cells engineered to overexpress neurotrophic factors have been demonstrated to result in significant attenuation of ganglion cell loss in animal models of different optic neuropathies. Cell-based combinatorial neuroprotective approaches represent a potential strategy to further increase the survival rates of retinal ganglion cells. However, data about the long-term impact of the different cell-based treatment strategies on retinal ganglion cell survival and detailed analyses of potential adverse effects of a sustained intraocular delivery of neurotrophic factors on retina structure and function are limited, making it difficult to assess their therapeutic potential.

Sign in / Sign up

Export Citation Format

Share Document